Rep. Tina Liebling
University of Minnesota-Rochester, Room 417, 111 S Broadway, Rochester MN
NOTE: This hearing will be part of mini-session and held in Rochester, Minnesota at the University of Minnesota-Rochester, Room 417
111 S Broadway, Rochester MN.
I. Overview of Pharmaceutical Drug Prices: Vincent Rajkumar, MD, Mayo Clinic
II. Recap of Prescription Drug Proposals and Next Steps
a. Pharmacy Benefit Manager Licensure Implementation: Peter Brickwedde, Assistant Commissioner, Minnesota Department of Commerce
b. Update on Prescription Drug Bills:
i. HF1246 (Morrison) Prescription Drug Price Transparency Act established, and report required.
ii. HF4 (Lesch) Drug manufacturer or distributor prohibited from charging unconscionable prices for prescription drugs; Board of Pharmacy, commissioner of
human services, and health plan companies required to notify the attorney general of certain prescription drug price increases; attorney general authorized to take
action against drug manufacturers and wholesalers related to price increases; and civil penalties imposed.
iii. HF1523 (Cantrell) Commissioner of human services directed to establish prescription drug purchasing program, and program authority and eligibility
III. Civica Overview: Eric Tichy, Vice Chair of Pharmacy Supply, Mayo Clinic
IV. Public Comment on Prescription Drug Pricing
Please contact Patrick McQuillan (Patrick.McQuillan@house.mn) and Krysta Niedernhofer (Krysta.Niedernhofer@house.mn) by Tuesday at 3 pm if you would like to give public testimony on Prescription drug pricing. The hearing will be informational.